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Abstract
Background: DNA microarrays can detect tuberculosis and its multi-drug resistant form in M. tuberculosis isolates
and sputum specimens with high sensitivity and specificity. However, no performance data currently exists for its
use in spinal tuberculosis specimens. This study was aimed to assess the performance of the CapitalBio™ DNA
microarray in the detection of isoniazid (INH) and rifampicin (RMP) resistance in spinal tuberculosis compared
with the BACT/MGIT 960 system.
Methods: From March 2009 to December 2011, 153 consecutive patients from Southwest Hospital, Chongqing
with clinically and pathologically diagnosed spinal tuberculosis were enrolled into this study. Specimens collected
during surgery from the tuberculosis patients were subjected to M. tuberculosis species identification and
drug-resistance detection by the CapitalBio™ DNA microarray, and results were compared with those obtained
from the absolute concentration drug susceptibility testing.
Results: The CapitalBio™ DNA microarray achieved 93.55% sensitivity for the correct M. tuberculosis species
identification of the 93 specimens that tested positive for spinal tuberculosis through culture. In addition,
twenty-seven additional patients (45.0%) were detected by the DNA microarray to be positive for M. tuberculosis
among sixty spinal tuberculosis patients who were culture negative. Moreover, the DNA microarray had a
sensitivity of 88.9% and a specificity of 90.7% for RMP resistance, and the microarray had a sensitivity of 80.0%
and a specificity of 91.0% for INH resistance. The mean turn-around time of M. tuberculosis species identification
and drug resistance detection using the DNA microarray was 5.8 (range, 4–9) hours.
Conclusions: The CapitalBio™ DNA microarray is a feasible and accurate tool for the species identification of
M. tuberculosis and for directly detecting RMP and INH resistance from spinal tuberculosis specimens in fewer
than 9 hours.
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Background
Multi-drug resistant tuberculosis (MDR-TB) is becoming
a serious public-health concern in developing countries.
The World Health Organization (WHO) has estimated
that there are 440,000 incident MDR-TB cases, and
150,000 persons with MDR-TB died worldwide in 2008
[1]. China is currently ranked 1st among the 27 countries
with the highest burden of MDR-TB and extensively
drug-resistant tuberculosis (XDR-TB) in the world [1]. As
the most common extrapulmonary tuberculosis, spinal
tuberculosis can lead to severe complications and is also
facing the problem of drug resistance. The emergence of
drug-resistant spinal tuberculosis may lead to an increased
number of relapses and initial treatment failures [2]. There-
fore, early diagnosis of drug resistance is essential to the
optimal management of drug-resistant spinal tuberculosis.
Conventional drug susceptibility testing (DST) can
provide definitive results, but this approach is time-
consuming and usually requires several weeks to pro-
duce susceptibility profiles, can lead to inadequate treat-
ment and further acquired resistance during this period
[3]. Moreover, DST for tuberculosis spondylitis is not
performed routinely in most resource-poor hospitals in
China because of the biosafety concerns and inadequate
infrastructure, which present a major hindrance for the
treatment of the disease. Therefore, there is an urgent
need to develop accurate, rapid and feasible molecular
methods to detect the drug-resistance.
Recently, a multitude of commercial molecular DST
kits, such as INNO-LiPA, Genotype MDR-TBplus, Capi-
talBio™ DNA microarray and Xpert MTB/RIF, have been
developed for the detection of mutations associated with
resistance to RMP and INH [4-12]. Among them, the
CapitalBio™ DNA microarray that incorporate specific
nucleotides at a given position of the rpoB, inhA and
katG gene has been developed by CapitalBio Corpor-
ation to detect tuberculosis and its multi-drug resistant
form in M. tuberculosis isolates and sputum specimens
with notable sensitivity and specificity [6,11,12]. Previous
study reported that the system had an accuracy of 91.8%
in RMP susceptibility prediction and 70.2% in INH, com-
pared with phenotypic DST [11]. However, there is no
data to support this technique’s application for testing
spinal tuberculosis specimens. In our study, we aimed to
access the feasibility and accuracy of the CapitalBio™
DNA microarray for parallel species identification and
detection of mutations that confer INH and RMP resist-
ance among consecutive spinal tuberculosis patients.
Materials and methods
Study design
From March 2009 through December 2011, we per-
formed this prospective validation study in Southwest
Hospital, Chongqing, China. One hundred and fifty-three
consecutive patients with clinically and pathologically
diagnosed spinal tuberculosis were enrolled into this
study. Clinical specimens (e.g., pus, caseous or granula-
tion tissue) were collected during surgery and were
divided into two aliquots for tuberculosis detection; one
of the aliquots was subjected to species identification and
detection of gene mutations by the CapitalBio™ DNA
microarray (CapitalBio Corp., Beijing, China), and the
other aliquot was processed for culture and DST. The
study was approved by the Ethics Committee of South-
west Hospital. Written informed consent was obtained
from all of the patients.
Diagnostic criteria for the spinal tuberculosis
Diagnosis of spinal tuberculosis was made with reference
to clinical and radiological findings and was verified
histopathologically after debridement in all patients.
Clinical and laboratorial presentation: Fever, night sweat
and weight loss, back pain, neurological signs, angular
deformity, positive response to anti-tuberculosis treat-
ment, relative lymphocytosis, a low level of haemoglobin
and a raised ESR. Radiology: X-ray, CT and MRI
revealed bone destruction, vertebral collapse, kyphosis,
tubercular lesions and paravertebral abscess. Histopath-
ology: Epitheloid granulomas, a granular necrotic back-
ground and lymphocytic infiltration.
CapitalBio™ DNA microarray design and preparation
Oligonucleotide probes were printed onto OPAldehydeslide
aldehyde-activated slides at a concentration of 10 μmol/L
in 50% dimethyl sulfoxide using a SmartArrayer-48 micro-
arrayer (both from CapitalBio Corp., Beijing, China) and
were covalently immobilized on the slides via an amino
group at their 5’ ends (spotting pattern shown in Figure 1).
In each array, sixteen oligonucleotide probes were
designed to detect mutations of rpoB (codons 531,
526, 513, 516, 511, 533), inhA (nucleotide-15 within
the promoter) and katG (codon 315) (Figure 1 a, b, c). In
addition, seventeen oligonucleotide probes were chosen in
several species-specific sequence regions of the 16S rRNA
gene for identification of different Mycobacterium species
(Figure 2).
Assay Procedure for the CapitalBio™ DNA microarray
Spinal tuberculosis specimens were subjected to DNA
microarray analysis at the Laboratory Department of
Southwest Hospital. Investigators and laboratory staff
were blinded to the culture and DST results of the clin-
ical specimens. The CapitalBio™ DNA microarray was
performed according to the manufacturer’s instructions
[11,12]. Briefly, 1–2 ml of the spinal tuberculosis spe-
cimen was inactivated for 30 min at 95°C followed by
sonication in an ultrasonic water bath for 25 min. Next,
the inactivated specimen was liquefied with an equal
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volume of liquefying solution (containing 0.5% N-acetyl-
cysteine, 1.45% trisodium citrate and 2% NaOH) for 30
min at 37°C. After inactivation and liquefaction, 1 ml of
the specimen was centrifuged at 12000 rpm for 5 min to
pellet the bacteria. Following centrifugation, the super-
natant was discarded, and the pellet was resuspended in
1 ml of 0.9% (w/v) saline and centrifuged at 12000 rpm
for 5 min. This supernatant was subsequently discarded,
and the pellet was resuspended in 50 μl of 10 mM Tris-
EDTA buffer and then transferred to an extraction tube.
The total DNA was isolated from the sample by
vortexing the tube at maximum speed in an Extractor™
36 (CapitalBio) for 5 min. Next, the extraction tube was
incubated at 95°C for 5 min, centrifuged briefly and the
supernatant was stored at −20°C until use. Next, asym-
metric PCR was performed on the samples by a Peltier
PTC225 thermal cycler (MJ Research, Watertown, MA)
for two amplification rounds according to the manu-
facturer’s instructions. Following PCR amplification, chip
hybridization was performed on the samples in a three-
dimensional tilting agitator BioMixer II hybridization; an
automated SlideWasher-8 (both from CapitalBio) was
Figure 2 Schematic diagram of the DNA probe array for different Mycobacterium specimens. Seventeen oligonucleotide probes were
chosen in several species-specific sequence regions of the 16S rRNA gene for identification of different Mycobacterium species. All probes were
immobilized horizontally five times.
Figure 1 Schematic diagram of the DNA probe array for rpoB, katG and inhA detection. a. The biochip contains two microarrays and two
specimens can be analyzed in parallel; for each array, one sub-array is for RMP, and the other is for INH. b. Six rpoB wild-type probes and thirteen
mutation-type probes were designed for the detection of RMP resistance. c. For the detection of INH resistance, one probe covers the wild-type
codon 315 of katG and two mutation-type probes for the same region, while one wild-type probe and one mutation-type probe detect the
inhA promoter region. All probes were immobilized horizontally for five times. QC: quality controls, EC: external controls, BC: blank controls,
NC: negative controls, IC: internal controls, WT: wild type.
Zhang et al. BMC Infectious Diseases 2012, 12:303 Page 3 of 7
http://www.biomedcentral.com/1471-2334/12/303
then used to wash and dry the hybridized slides. The
fluorescent signal on the slides that was emitted by the
microarrays was detected using a GeneArray scanner
(LuxScan™-10K confocal laser scanner, CapitalBio,
China), and the fluorescence intensities were quantified
by the tailor-made software developed by CapitalBio.
The whole protocol took less than 9 h to perform, with
up to 4 specimens being analyzed for M. tuberculosis
identification and 2 specimens being analyzed for drug
resistance detection in parallel.
Conventional culture and DST
The quality-assured culture and DST was conducted
using the BACT/MGIT 960 system and the absolute
concentration method on L-J medium at the Depart-
ment of Clinical Laboratory, Infectious Disease Medical
Center in Chongqing. The specimens were processed
according to standard methodologies [13]. The following
critical concentrations were used respectively: 1 and
10 μg/ml for INH, and 50 and 250 μg/ml for RMP.
Results
Study population
We enrolled a total of 153 patients with spinal tuber-
culosis at Southwest Hospital during the study period.
Among the 153 patients, 76 were female and 77
were male. The mean age was 36.4 years (range, 4 to
76 years). A total of 77.1% (118/153) of the patients were
initial treatment cases, and the remaining 22.9% (35/153)
were retreatment cases who had received previous chemo-
therapy for a mean period of 7.1 months (range, 3 to 74
months) at the time of enrollment. None of the patients
was HIV-seropositive.
The results of conventional culture and DST
Among the 153 specimens that were cultured, a total of
60.1% of the specimens (93/153) produced a positive
culture. Following culture testing, the positive specimens
were subjected to DST. The results of the DST using the
absolute concentration method on L-J medium showed
that a total of 15/93 (16.13%) isolates were resistant to
INH, 18/93 (19.35%) were resistant to RMP, and 11/93
(11.83%) of these isolates were resistant to both INH
and RMP (MDR-TB). The mean turnaround time of
culture and DST was 56.8 days (range, 49 to 77 days).
Strain identification of M. tuberculosis using the
DNA microarray
Among the 153 spinal tuberculosis specimens, 114 samples
were identified to contain M. tuberculosis strains by the
DNA microarray, and the positive detection rate was
74.51%. Among the 93 patients with culture-positive tuber-
culosis, the overall sensitivity of the M. tuberculosis identifi-
cation by the DNA microarray was 93.55% (87/93). The
sensitivity was 97.4% for smear- and culture-positive
cases and 73.3% for smear-negative, culture-positive
cases (Table 1). The hybridization pattern of the M.
tuberculosis identification was shown in Figure 3a.
Detection of the RMP and INH resistance using the
DNA microarray
Detection of M. tuberculosis rpoB mutants
Taking the results of the phenotypic DST into account,
the DNA microarray correctly detected rpoB mutations
in 16 of the 18 patients with RMP resistance (88.89%
sensitivity). The RMP-resistant samples displayed differ-
ent mutations: 56.3% (9/16) of the samples had muta-
tions at codon 531, 25.0% (4/16) had mutations at codon
526, and 18.8% (3/16) had mutations at codon 516. Add-
itionally, one of the 18 (5.6%) RMP-resistant specimens
produced the wild-type hybridization pattern on the
DNA microarray, repeat testing and sequencing also
revealed the wild-type pattern. Moreover, one of the
18 specimens (5.6%) failed to produce the hybridization
pattern. Part of the hybridization patterns for the RMP-
resistant samples was shown in Figure 3b, c. Two of the
75 (2.7%) RMP-susceptible specimens showed mutations
at codon 533 (CTG->CCG), and one specimen showed a
mutation at codon 513 (CAA->CCA). Four specimens
(5.3%) failed to produce the pattern of the mutation.
Regarding RMP resistance detection, the sensitivity and
specificity of the DNA microarray were 88.9% and
90.7%, respectively (Table 2).
Detection of M. tuberculosis inhA and katG mutants
Of the 15 INH-resistant specimens, 8 specimens (53.3%)
had a mutation in katG (codon 315), which is the most
common mutation found in INH-resistant strains. Three
of the specimens (20.0%) had a mutation in the inhA
gene, C15T. Additionally, two low-level INH-resistant
specimens (13.3%) displayed the wild-type hybridization
pattern on the DNA microarray, and 2 of the specimens
(13.3%) failed to produce the hybridization pattern. Part
of the hybridization pattern of the INH-resistant isolates
was shown in Figure 3d, e. Moreover, three of the 78
INH-susceptible samples (3.9%) showed a mutation at
nucleotide 15 within the promoter of the inhA, and 4 of
the 78 INH-susceptible samples (5.1%) failed to produce
and results. The sensitivity and specificity of the INH
resistance detection by the DNA microarray were 80.0%
and 91.0%, respectively (Table 2). The mean turnaround
time of M. tuberculosis identification and drug-resistance
detection using DNA microarrays was 5.8 hours (range,
4 to 9 hours).
Discussion
To respond to the urgent need for rapid and accurate
detection of M. tuberculosis and drug resistance, a DNA
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microarray system was developed by the CapitalBio Cor-
poration. This microarray can simultaneously identify 17
mycobacterial species by targeting the species-specific
sequences in the 16S rRNA. Moreover, the specialized
microarray consists of 16 oligonucleotide probes, which
allowed the detection of the 13 most common mutations
in the rpoB gene, 2 mutations in the katG gene, and one
mutation in the promoter region of the inhA gene. In
our study, the identification of M. tuberculosis strains
and detection of their resistant form in spinal tubercu-
losis specimens were evaluated by the CapitalBio™ DNA
microarray assay.
We evaluated the utility of the CapitalBio™ DNA
microarray in 153 consecutive spinal tuberculosis sam-
ples. The microarray system identified more than 93% of
all cases with culture-confirmed spinal tuberculosis, in-
cluding more than 73% of patients with smear-negative
cultures. Moreover, this assay was positive in 45% (27/60)
of the patients who were not confirmed by M. tubercu-
losis culture but were demonstrated both clinically and
pathologically to have spinal tuberculosis. Results of the
study revealed that the microarray assay has a higher sus-
ceptibility compared with the conventional BACT/MGIT
960 system for the detection of M. tuberculosis strains.
Previous studies conducted by Guo and Zhu et al. also
reported that for the direct detection of M. tuberculosis
complex bacteria the overall sensitivity obtained with this
commercial DNA microarray were 100% [11,12]. The
negative control of the species identification has not been
setup considering the following reasons: First, Guo and
Zhu respectively found that the specificity of the Capital-
Bio™ DNA microarray was 100% for the species identifi-
cation of M. tuberculosis [11,12]. Second, recruitment and
enrollment of pyogenic spondylitis patients, with similar
clinical characteristics and clinical specimens to spinal tu-
berculosis, are relatively difficult in our department. How-
ever, absence of the negative control might be a potential
limitation of this study.
For the detection of anti-tuberculosis drug resistance,
the DNA microarray had a sensitivity of 73.3% and
specificity of 91.0% for INH resistance, and a sensitivity
of 88.9% and specificity of 90.7% for RMP resistance.
Interestingly, 5.6% of phenotypically defined RMP-
resistant specimens and 13.3% of INH- resistant speci-
mens had no mutations in related genes, suggesting that
other mechanisms or mutations in other codons of the
related genes may be responsible for the emergence of
RMP and INH resistance. Moreover, a small proportion
of specimens failed to produce results; one possible rea-
son for the lack of results may be because of the exigu-
ous M. tuberculosis bacilli contained in some specimens,
or the DNA amplification inhibitors in the clinical speci-
mens, resulting in a lack of DNA being extracted from
these samples. Results of the DNA microarray assay
could be obtained within a mean turnaround time of 5.8
hours from the start of the analysis.
Figure 3 Hybridization pattern of spinal tuberculosis specimens with the DNA microarray. a. Hybridization pattern of the M. tuberculosis
strain identification (white frame) b. RMP resistance with the rpoB 531 (TCG->TTG) mutation, the hybridization signal of probe TCG531TTG (solid
rectangle) being higher than corresponding wild-type probe (dashed rectangle) c. RMP resistance test: rpoB 516 (GAC->GTC) mutation, the
hybridization signal of probe GAC516GTC (solid rectangle) being higher than corresponding wild-type probe (dashed rectangle) d, e. INH
resistance test: katG 315 (AGC->ACC) mutation, the hybridisation signal of probe katG AGC315ACC (solid rectangles) were higher than
corresponding wild-type probe (dashed rectangles) e. INH resistance test: inhA-15 C-T mutation, the hybridisation signal of probe inhA 15C→T
(solid rectangles) were higher than corresponding wild-type probe (dashed rectangles).








Correct-no./total no. (%) 87/93 (93.55) 76/78 (97.44) 11/15 (73.33)
95% CI 88.56-98.54 93.93-100.00 50.95-95.71
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Recently, some novel molecular DST methods based on
nucleic acid amplification have been available. Among
them, the Xpert MTB/RIF assay was endorsed by the
WHO as a replacement for sputum smear microscopy
[7,8,14-16]. Compared with the Xpert MTB/RIF assay, the
CapitalBio™ microarray system has some limitations, e.g.,
the assay is semi-automatic, requires more experienced
technical skills for manual manipulation and has more op-
portunities to create biohazard intermediates. However, the
microarray system has two advantages compared to the
Xpert MTB/RIF assays. First, the microarray assay is less
costly because cartridges of the Xpert MTB/RIF are dispos-
able. Second, the microarray assay can detect the gene
mutations associated to both RMP and INH.
In addition, compared with isolates and sputum
samples, the application of the DNA microarray in
spinal tuberculosis samples is far more complex because
of the diversity of clinical sample types, difficulties in
obtaining adequate tissue for analyses and the methods
of processing samples prior to analysis [14].
Conclusions
Overall, the CapitalBio™ DNA microarray is a simple
and accurate tool for M. tuberculosis identification and
for the diagnosis of RMP and INH resistance, demon-
strating that the system is likely to be applicable to
spinal tuberculosis specimens. The automated readout
and short turnaround time make this assay suitable for
testing and decreases delays in diagnosis, without the
need to build large numbers of advanced biosafety facil-
ities. Nevertheless, the infrastructure and trained
personnel required for this system are still not available
except in a limited number of reference laboratories,
which dramatically reduces its clinical utility in poverty-
stricken zones. Thus, the integral and fully automatic
DNA microarray system should be developed, which
would have direct benefits to workflows and to biosafety
in resource-scarce settings. The gene mutations that re-
late to other first-line and second-line drug resistance
should be considered for incorporation into the further
DNA microarray system because of the dissemination of
second-line drug-resistant M. tuberculosis strains. Add-
itional large-scale studies are needed to more further
evaluate its diagnostic performance in spinal tuberculosis.
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